In Part One, the authors addressed the relevance of genetic information, and how race and genetics have affected and may impact the development of medicines, pharmacogenomics, and personalized medicine in the United States.* Part Two examines current and proposed federal and state laws and regulations intended to protect individuals from the misuse of genetic information, including uses that discriminate based on genetic predispositions. This Part next explores the potential for litigation against both manufacturers and providers, as well as potential defenses. The authors also discuss legal issues relating to research that relies on the use of genetic information.
[Corrine Parver et al.] American Health Lawyers Association’s Advisory Council on Racial and Ethnic Diversity. “Patient-Tailored Medicine, Part Two: Personalized Medicine and the Legal Landscape.” Journal of Health & Life Sciences Law 2, no. 2 (January 2009): 1-43. © 2009 American Health Lawyers Association. All rights reserved.